<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050206</url>
  </required_header>
  <id_info>
    <org_study_id>4360</org_study_id>
    <secondary_id>F1D-MC-HGIU</secondary_id>
    <nct_id>NCT00050206</nct_id>
  </id_info>
  <brief_title>Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder</brief_title>
  <official_title>Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy (how well the drug works), safety, and
      any side effects of olanzapine compared to placebo in the treatment of mania in bipolar
      disorder in adolescents. Both the potential benefits and side effects of olanzapine will be
      evaluated throughout this trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of a flexible dose of olanzapine compared with placebo in the treatment of mania in bipolar I disorder (manic or mixed episode associated with bipolar I disorder, with or without psychotic features) in adolescents</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess additional efficacy as measured by Y-MRS,CGI-BP Severity of Illness, CGI-BP Severity of Illness (CGI-BP Severity of Mania, CGI-BP Severity of Depression, and CGI-BP Severity Overall)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess additional efficacy as measured by Childrenâ€™s Depression Rating Scale-Revised (CDRS- R);Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IVPI) and Overt Aggression Scale (OAS).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of olanzapine and quality of life associated with olanzapine compared with placebo.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the frequency of response of up to 3-weeks, double-blind treatment and up to an additional 26 weeks of open-label olanzapine treatment</measure>
  </secondary_outcome>
  <enrollment>130</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 13 to 17 years of age who must not yet have reached their
             18th birthday prior to Visit 1, when informed consent is obtained.

          -  Patients must have a diagnosis of bipolar I disorder and currently display an acute
             mania or mixed episode.

          -  Both the patient and the patient's parent/authorized legal representative must
             understand the nature of the study and must sign a document granting consent.

          -  Female patients of child-bearing potential must test negative for pregnancy at the
             time of enrollment based on a serum pregnancy test.

        Exclusion Criteria:

          -  Female patients who are either pregnant or nursing.

          -  Current diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective
             disorder.

          -  Patient with acute or unstable medical conditions, such that intensive care unit
             hospitalization for the disease is anticipated within 6 months.

          -  Patients who have previously not responded to an adequate dose and/or duration of
             olanzapine treatment.

          -  Patients who have been judged clinically to be serious suicidal risks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2002</study_first_submitted>
  <study_first_submitted_qc>November 26, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2002</study_first_posted>
  <last_update_submitted>June 11, 2007</last_update_submitted>
  <last_update_submitted_qc>June 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

